BIIB 250502 75.00C(BIIB250502C75000) Stock Price Today | Quotes & News - Moomoo

US OptionsDetailed Quotes

BIIB250502C75000

Watchlist

46.66
0.000.00%

15min DelayClose May 2 15:56 ET

0.00High0.00Low

Intraday

5D
Daily

News

J.P. Morgan Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $175
Moomoo News19:31 ET · Ratings
JP Morgan Maintains Neutral on Biogen, Lowers Price Target to $175
BenzingaMay 5 10:30 ET · Ratings
New Analyst Forecast: $BIIB Given $187.0 Price Target
Quiver QuantitativeMay 5 10:20 ET
BTIG Maintains Biogen(BIIB.US) With Hold Rating
Moomoo NewsMay 5 07:31 ET · Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: OKYO Pharma Limited Sponsored ADR (OKYO), Biogen (BIIB) and Cigna (CI)
TipRanksMay 5 07:00 ET · Ratings
Piper Sandler Keeps Their Hold Rating on Biogen (BIIB)
TipRanksMay 5 07:00 ET · Ratings

Comments

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

$Biogen (BIIB.US)$
Breakthrough: First-Ever Drug to Slow Early Alzheimer's Gets EU Green Light

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

1

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

$Organon & Co (OGN.US)$ $Biogen (BIIB.US)$
Organon Claims US Market Leadership with Groundbreaking Tocilizumab Biosimilar Deal

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

$Biogen (BIIB.US)$
Biogen's Bold Move: 580,000 sq ft Innovation Powerhouse to Transform Kendall Square Research Hub

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

$Biogen (BIIB.US)$
Biogen's Breakthrough Drug Enters Final Testing Phase for Critical Kidney Transplant Complication

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

confirmed bottom

$Biogen (BIIB.US)$ confirmed technical bottom

Read more